{"name":"Berlin-Chemie Menarini","slug":"berlin-chemie-menarini","ticker":"","exchange":"","domain":"","description":"Berlin-Chemie Menarini is a leading pharmaceutical company with a strong focus on developing and commercializing innovative treatments. The company has a diverse portfolio of products and is known for its commitment to research and development in various therapeutic areas.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Corvitol","genericName":"Corvitol","slug":"corvitol","indication":"Other","status":"phase_3"},{"name":"Nebilet","genericName":"Nebilet","slug":"nebilet","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Corvitol","genericName":"Corvitol","slug":"corvitol","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nebilet","genericName":"Nebilet","slug":"nebilet","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNTkpENkEtQlRmamNPVmVyZWJtdkd4TmYxSVRGWkRDNXZFdGRzN05TQk8xcXdNa3FMVEJ3SFZmNjB4aFh3RUh3dWJOaFNPcWNtUVVMOE1XZ01yVFJpUGhRSzA2ekdnZV80OHdDLVdSN1NLVVgxemEtZHBpTEN3NkxaQU5DUXROUEhNWGdTUllIYjV2WnQzZkxmM2xjQVlUUEhnQjRiRDZR?oc=5","date":"2026-04-05","type":"pipeline","source":"IndexBox","summary":"Oral Weight-Loss Drug Battle: Novo Nordisk vs Eli Lilly's New Treatments - News and Statistics - IndexBox","headline":"Oral Weight-Loss Drug Battle: Novo Nordisk vs Eli Lilly's New Treatments - News and Statistics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQeWJCUGFjRXFVcExqQkM0NmpjRjdKdEpKanI5ZWpJb3pqU0lPcHdXZG4tQnBVdUFBbEczdFpSVE9DWmhranlLWXFoeTFBd1NpNjZVdTFYbUdtWGN2ZGdLNFh3R2s4MXJfbnVPRlNHMjFkdHYtLXZFVUt0MG1WeE0zYWIwTjNfRVVWTXpBTDB2SFQtamVkNUJleTRkYnNnbUtrSW9GNk1pNmg3MFd1dWxxQ0hOc1ZtYUFrSWR2RVFIdGVleVhwaHZXM2xYZ0Y?oc=5","date":"2026-03-30","type":"pipeline","source":"საქართველოს პარლამენტი","summary":"At the sitting of the Interim Commission of the Parliament, representatives of pharmaceutical companies were heard - საქართველოს პარლამენტი","headline":"At the sitting of the Interim Commission of the Parliament, representatives of pharmaceutical companies were heard - საქ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNODFWTUpBTWl4MXktdlp1OGFrcEJYQ19VN0ZiNi1XYmtrZUxMMW95MFRqNUVEUXAtUG05UUxKZkRQSXVrWmZINnhNeDZXVDhOVkNyQ3lGSU5BaWpMMEFHQnh5ZERpWVNQZ19HNkV3RFpLblltNno4RjdoSW9VZTNfTDdRTzdkYTVBVkhZNF9zblhLVFNPWjl6ODFwd1NUcEJWSTNkRWxZa1F6N0x4?oc=5","date":"2026-03-30","type":"pipeline","source":"1TV.GE","summary":"Parliamentary Commission reviews medicine pricing with pharmaceutical companies - 1TV.GE","headline":"Parliamentary Commission reviews medicine pricing with pharmaceutical companies - 1TV.GE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPZE9SSmhjY1ZHRUJkQ3hWX2VXc0s0Z3A1VTc3NWJoa3hFS1didW1jRXZaajZjaFZxUmtEZklULThyRVZIblZkSHpXR0p6Rnl1Tm4xMmlWSUcwWVU5ZlJnZHVQeEtFai1yZmFxazA1RVM1MDgwMXJiU3BQWEg2aGNuQmVZZmgzUWVSdUtUYkl3dkdUd9IBkgFBVV95cUxPZE9SSmhjY1ZHRUJkQ3hWX2VXc0s0Z3A1VTc3NWJoa3hFS1didW1jRXZaajZjaFZxUmtEZklULThyRVZIblZkSHpXR0p6Rnl1Tm4xMmlWSUcwWVU5ZlJnZHVQeEtFai1yZmFxazA1RVM1MDgwMXJiU3BQWEg2aGNuQmVZZmgzUWVSdUtUYkl3dkdUdw?oc=5","date":"2025-06-17","type":"pipeline","source":"Новости GxP","summary":"Russians’ spending on thyroid medications increased by 20% - Новости GxP","headline":"Russians’ spending on thyroid medications increased by 20% - Новости GxP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPMGx1RUhta1VwTm5hVFc1bWs2dV9TcjR4NWd2R3BlUzZRSzVUMU1ObGVIMDhKZTRkTHVSTVJJRGRnbVpFbDZ4MkdpaEw4bTRndjk0R0ZHSWY4d3daOE1TTFBlUDVVS0pWTDV5ZGdqN2pFcUVDRl9tQW5WektaZkpodjlTVm96OGEtUzlicXB3bjQ5U3hGWF9qd2VXTEJ3ZmVURldGWDlRdzctTFdTQWR6OXlfbGQ3c2ducTZaeA?oc=5","date":"2023-10-24","type":"pipeline","source":"European Medical Journal","summary":"Exploring Type 2 Inflammation in Chronic Obstructive Pulmonary Disease - European Medical Journal","headline":"Exploring Type 2 Inflammation in Chronic Obstructive Pulmonary Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiSEFVX3lxTFBITUxwbURweUs3LWJSeF9KTGhzSTNTMG1mcUtUSE1IT2F0RGxZbHB1NEJHZ0wtZk1jMXRaSXhZTkQybXFRM0RlLQ?oc=5","date":"2023-07-03","type":"pipeline","source":"Università della Svizzera italiana | USI","summary":"Pietro Corti, International Marketing Trainee, Menarini Berlin-Chemie - Università della Svizzera italiana | USI","headline":"Pietro Corti, International Marketing Trainee, Menarini Berlin-Chemie - Università della Svizzera italiana | USI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPeFNDUjBvSnJuaURGVEdra2l1XzdNcFozdjVtazZqNEgxYkNFNUk3TGZQVE5tR0E1NUJlWmNDX19tNGpnYk02WWItZjZ1bGRrMV9YSFZwMFF3MkpKWWluMHhfVzdBVnY1V1g2NHVXZ1hKSkJuSDNvZ2NPZkhnX09HZXlaUGJXRWsxdTVEbHpJQ2d1eUhCQVlSTjJyd2U4aUt1MWV5cTM2Ty0zUHVxUTdZU3h1WVpFR2xybWww?oc=5","date":"2023-03-21","type":"patent","source":"JUVE Patent","summary":"Insulet and Peterreins Schley win PI over insulin pumps at Düsseldorf Regional Court - JUVE Patent","headline":"Insulet and Peterreins Schley win PI over insulin pumps at Düsseldorf Regional Court","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWlBkdnJENHZOcTJkWFJzM01TMXc4R3JqRGZDdklDU1Q0UnZtX21VeHdWWHp4eEM2ZmR6c3pSZ0lqNXpkeFV5a3hJUm5fWWw0cFZoalgyb05HeHBhY3Braks1Wkx0MFJjY3AwQUo4dWc0M096bkg3aHZEdHFxdTBUOGlRLXZLODdvcjdoaUplTk1wMnNlakRuTTFqZWV3WXRuQWpKTFBSNFM?oc=5","date":"2022-12-19","type":"pipeline","source":"politico.eu","summary":"Bitter pills: Europe and Ukraine divided over pharma sanctions - politico.eu","headline":"Bitter pills: Europe and Ukraine divided over pharma sanctions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxQWW0xbFltbTNnZDFWUDN5RHFEMGpCWDJSMU5xTzR6OUR6UlFleTd5OGZoNUl2N3dBSDJBM3dldDNJRzRkUUZ5T3I5WGtCalR5UVluQk1tV0pWdURZM2wyNFl6eE1YRDYtUThINUZlN0RZaGptZXJQQ3pXUGJ1SFRJMmlHbC1yQVZtdFhabVlFNkxvSkdhQmZTaDlEakFsRzVnWDgxSjNpVjBIcjFWX29PWHpUcWFoMmVjVXRKWGJycW9Qc3p0aloxdHlRbHlGVUw0b3NvNEItbDlIU3dodkIxSnlIcUpGaGJKZktaWk5QRWFKZEgweG83QTBQSlRQWjAtYU5HWlN5UTI0aGs?oc=5","date":"2022-06-06","type":"pipeline","source":"legalblogs.wolterskluwer.com","summary":"VAT Fixed establishment = permanent establishment? or, should direct and indirect tax practitioners talk to each other? - legalblogs.wolterskluwer.com","headline":"VAT Fixed establishment = permanent establishment? or, should direct and indirect tax practitioners talk to each other?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTFBkaFE5UHJnVXZBcHJxR0xabVVlSS1ObmJrMUFPMTBvSVd3cW1DYk4wOEd6eFdFaDFRQXVVbnJPMjBRNnJCUks4YjQzZ3dQTm11UkJUTEdPaG12dnFSLS1mWk96bUVpNF9aVW55RnNNa05tTEU?oc=5","date":"2017-11-24","type":"regulatory","source":"CHEManager","summary":"The German Capital Region - CHEManager","headline":"The German Capital Region","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPTEY5VkFIekcxZGtaekNtdUNfdVBsdDdUNzdCdXFJc29KZjdNc0pobU43b09oZy1STjdEeGVrUXZDMndmYzE4SmloQS0tN1dDSk1hZjZwSlZsaFFjZHRySjZKaTBLeHdQOGlhU3FyU2k2NGxrbDhlMXV5YkpZeThCTDdKUWJDQ3lCNVZBbXdvSWRBUGdlMFBhQ0ZPYkw1VTg?oc=5","date":"2016-11-28","type":"deal","source":"Fierce Biotech","summary":"Chugai licenses out early-stage cancer candidate to Menarini - Fierce Biotech","headline":"Chugai licenses out early-stage cancer candidate to Menarini","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNcW5WeDY1UllFenpjVUE1NE5nRUJqb3pHMnkxTFFXeUNhOVJ5ckJ4Wl9Fdl9TS0liOGtoQ2ZIRkptblA0VlluQ2dwTkJyNTJqcG5NWDE0bG9MWHV3TnlWeEZSRHBNTEJwVGp4b2Q2NTIzdmhNSF9DNTdoQkRlZ2VUNUhFV1hZbjZKcnp0OHV4d0JiaGZqajRWOVdwaHl0Y3B5M1ZjWFBYX3Vrb25MRzZLajViWkVVT0RFRFBfQnc0eGtUODJxRGp1YV96b0dhZFdzeFlDRVhR?oc=5","date":"2016-06-07","type":"pipeline","source":"PR Newswire","summary":"Haselmeier Announces the German Launch of the BerliPen® areo 3 Through Berlin-Chemie - PR Newswire","headline":"Haselmeier Announces the German Launch of the BerliPen® areo 3 Through Berlin-Chemie","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}